Allergic conjunctivitis: The evolution of therapeutic options

Allergy and Asthma Proceedings

Volumn 33, Issue 2, 2012, Pages 129-139

  Bielory, Leonard ^a,b  

^a ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL   (United States)

^b STARx Allergy and Asthma Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALCAFTADINE; ANTAZOLINE; AZELASTINE; BEPOTASTINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYCLOSPORIN; DECONGESTIVE AGENT; EMEDASTINE; EPINASTINE; KETOROLAC; KETOTIFEN; KETOTIFEN FUMARATE; LEVOCABASTINE; LODOXAMIDE; LOTEPREDNOL; LOTEPREDNOL ETABONATE; NAPHAZOLINE; NEDOCROMIL; OLOPATADINE; PEMIROLAST; PHENIRAMINE MALEATE;

ALLERGIC CONJUNCTIVITIS; DRUG DELIVERY SYSTEM; DRY EYE; ENVIRONMENTAL EXPOSURE; EYE ALLERGY; EYE INFLAMMATION; HUMAN; REVIEW; TREATMENT OUTCOME;

ALLERGENS; ANTI-ALLERGIC AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CONJUNCTIVITIS, ALLERGIC; DRUG DISCOVERY; DRY EYE SYNDROMES; HISTAMINE H1 ANTAGONISTS; HISTORY, 20TH CENTURY; HUMANS; NASAL DECONGESTANTS; OPHTHALMIC SOLUTIONS; POLLEN;

EID: 84860228703     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2012.33.3525     Document Type: Review

References (113)

1. Dart JK, Buckley RJ, Monnickendan M, and Prasad J. Perennial allergic conjunctivitis: Definition, clinical characteristics and prevalence. Trans Ophthalmol Soc U K 105:513-520, 1986.
2. Singh K, Axelrod S, and Bielory L. The epidemiology of ocular and nasal allergy in the United States, 1988-1994. J Allergy Clin Immunol 126:778-783, e776, 2010.
3. Bielory L, Chun Y, Bielory BP, et al. Impact of mometasone furoate nasal spray on individual ocular symptoms of allergic rhinitis: A meta-analysis. Allergy 66:686-693, 2011.
4. Pitt AD, Smith AF, Lindsell L, et al. Economic and quality-oflife impact of seasonal allergic conjunctivitis in Oxfordshire. Ophthalmic Epidemiol 11:17-33, 2004. (Pubitemid 38367076)
5. Smith AF, Pitt AD, Rodruiguez AE, et al. The economic and quality of life impact of seasonal allergic conjunctivitis in a Spanish setting. Ophthalmic Epidemiol 12:233-242, 2005. (Pubitemid 41702805)
6. Palmares J, Delgado L, Cidade M, et al. Allergic conjunctivitis: A national cross-sectional study of clinical characteristics and quality of life. Eur J Ophthalmol 20:257-264, 2010.
7. Ono SJ, and Lane K. Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis. Drug Des Devel Ther 5:77-84, 2011.
8. Trocme SD, Gleich GJ, Kephart GM, et al. Eosinophil granule major basic protein inhibition of corneal epithelial wound healing. Invest Ophthalmol Vis Sci 35:3051-3056, 1994. (Pubitemid 24186407)
9. Messmer EM, May CA, Stefani FH, et al. Toxic eosinophil granule protein deposition in corneal ulcerations and scars associated with atopic keratoconjunctivitis. Am J Ophthalmol 134:816-821, 2002. (Pubitemid 35425448)
10. Jedrzejczak-Czechowicz M, Lewandowska-Polak A, Jarzebska M, et al. Mast cell and eosinophil activation during early phase of grass pollen-induced ocular allergic reaction. Allergy Asthma Proc 32:43-48, 2011.
11. Wyman M. Autumnal Catarrh. Cambridge: Hurd and Houghton, 18-12, 1876.
12. Noon L, and Cantab BC. Prophylactic innoculation against hay fever. Lancet 1:1572-1574, 1911.
13. Korting HC, Schafer-Korting M, Hart H, et al. Anti-inflammatory activity of hamamelis distillate applied topically to the skin. Influence of vehicle and dose. Eur J Clin Pharmacol 44:315-318, 1993. (Pubitemid 23153446)
14. Blumenthal M. New World plants; New World drugs. Allergy Proc 13:345-352, 1992. (Pubitemid 23058335)
15. Bielory L, and Heimall J. Review of complementary and alternative medicine in treatment of ocular allergies. Curr Opin Allergy Clin Immunol 3:395-399, 2003. (Pubitemid 37254722)
16. Keeney EL. Histamine and antihistaminic drugs. California Med 72:377-389, 1950.
17. Simons FE. Advances in H1-antihistamines. N Engl J Med 351:2203-2217, 2004.
18. Tuft L, and Neish DD Jr. Comparative study of ophthalmic decongestants in allergic conjunctivitis. J Am Med Assoc 167:60-62, 1958.
19. Bredemeyer I, Graupner K, Hammer R, et al. Prothanon eyedrops. 2. Results of clinical test in double-blind experiment. Pharmazie 25:118-120, 1970.
20. Bielory L, Lien KW, and Bigelsen S. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs 65:215-228, 2005. (Pubitemid 40139383)
21. Abelson MB, Allansmith MR, and Friedlaender MH. Effects of topically applied occular decongestant and antihistamine. Am J Ophthalmol 90:254-257, 1980. (Pubitemid 10056134)
22. Abelson MB, Butrus SI, Weston JH, et al. Tolerance and absence of rebound vasodilation following topical ocular decongestant usage. Ophthalmology 91:1364-1367, 1984. (Pubitemid 15208906)
23. Duzman E, Warman A, and Warman R. Efficacy and safety of topical oxymetazoline in treating allergic and environmental conjunctivitis. Ann Ophthalmol 18:28-31, 1986. (Pubitemid 16105431)
24. Duzman E, Anderson J, Vita JB, et al. Topically applied oxymetazoline. Ocular vasoconstrictive activity, pharmacokinetics, and metabolism. Arch Ophthalmol 101:1122-1126, 1983. (Pubitemid 13067511)
25. Lanier BQ, Tremblay N, Smith JP, et al. A double-masked comparison of ocular decongestants as therapy for allergic conjunctivitis. Ann Allergy 50:174-177, 1983. (Pubitemid 13112679)
26. Miller J, and Wolf EH. Antazoline phosphate and naphazoline hydrochloride, singly and in combination for the treatment of allergic conjunctivitis-a controlled, double-blind clinical trial. Ann Allergy 35:81-86, 1975.
27. Spector SL, and Raizman MB. Conjunctivitis medicamentosa. J Allergy Clin Immunol 94:134-136, 1994. (Pubitemid 24219669)
28. Ballas Z, Blumenthal M, Tinkelman DG, et al. Clinical evaluation of ketorolac tromethamine 0.5% ophthalmic solution for the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol 38(suppl):141-148, 1993. (Pubitemid 23239420)
29. Toker MI, Erdem H, Erdogan H, et al. The effects of topical ketorolac and indomethacin on measles conjunctivitis: Randomized controlled trial. Am J Ophthalmol 141:902-905, 2006.
30. Donshik PC, Pearlman D, Pinnas J, et al. Efficacy and safety of ketorolac tromethamine 0.5% and levocabastine 0.05%: A multicenter comparison in patients with seasonal allergic conjunctivitis. Adv Ther 17:94-102, 2000. (Pubitemid 30419038)
31. Tinkelman DG, Rupp G, Kaufman H, et al. Double-masked, paired-comparison clinical study of ketorolac tromethamine 0.5% ophthalmic solution compared with placebo eyedrops in the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol 38(suppl):133-140, 1993. (Pubitemid 23239419)
32. Khosravi E, Elena PP, and Hariton C. Allergic conjunctivitis and uveitis models: Reappraisal with some marketed drugs. Inflamm Res 44:47-54, 1995.
33. Tauber J, Raizman MB, Ostrov CS, et al. A multicenter comparison of the ocular efficacy and safety of diclofenac 0.1% solution with that of ketorolac 0.5% solution in patients with acute seasonal allergic conjunctivitis. J Ocul Pharmacol Ther 14:137-145, 1998.
34. Leysen JE, and Gommeren W. Drug receptor dissociation time, new tool for drug research: Receptor binding affinity and drug receptor dissociation profiles of serotonin S2, dopamine D2, histamine H1 antagonists and opiates. Drug Develop Res 8:119-131, 1986. (Pubitemid 16078130)
35. Zuber P, and Pecoud A. Effect of levocabastine, a new H1 antagonist, in a conjunctival provocation test with allergens. J Allergy Clin Immunol 82:590-594, 1988. (Pubitemid 18261009)
36. Sharif NA, Xu S, and Yanni J. Emedastine: Pharmacological profile of a novel antihistamine for use in allergic conjunctivitis. Invest Ophthalmol Vis Sci 36:s135, 1995.
37. Yanni JM, Stephens DJ, Parnell DW, et al. Preclinical efficacy of emedastine, a potent, selective histamine H1 antagonist for topical ocular use. J Ocul Pharmacol 10:665-675, 1994.
38. Yanni JM, Stephens DJ, Miller ST, et al. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/ antihistaminic agent. J Ocul Pharmacol Ther 12:389-400, 1996. (Pubitemid 26405743)
39. Friday GA, Biglan AW, Hiles DA, et al. Treatment of ragweed allergic conjunctivitis with cromolyn sodium 4% ophthalmic solution. Am J Ophthalmol 95:169-174, 1983. (Pubitemid 13194662)
40. Johnson HG, VanHout CA, and Wright JB. Inhibition of allergic reactions by cromoglycate and by a new antiallergy drug U-42,585E. II. Activity in primates against aerosolized Ascaris suum antigen. Int Arch Allergy Appl Immunol 56:481-487, 1978. (Pubitemid 8300758)
41. Johnson HG, VanHout CA, and Wright JB. Inhibition of allergic reactions by cromoglycate and by a new anti-allergy drug U-42,585E. I. Activity in rats. Int Arch Allergy Appl Immunol 56:416-423, 1978. (Pubitemid 8300774)
42. Bloch-Michel E. Evaluation de l'efficacite therapeutique d'un collyre anti-allergique par test photographique. Rev Fr Allergol 30:163-165, 1990.
43. Fahy GT, Easty DL, Collum LM, et al. Randomised doublemasked trial of lodoxamide and sodium cromoglycate in allergic eye disease. A multicentre study. Eur J Ophthalmol 2:144-149, 1992.
44. Verin PH, Dicker ID, and Mortemousque B. Nedocromil sodium eye drops are more effective than sodium cromoglycate eye drops for the long-term management of vernal keratoconjunctivitis. Clin Exp Allergy 29:529-536, 1999. (Pubitemid 29179823)
45. Corin RE. Nedocromil sodium: A review of the evidence for a dual mechanism of action. Clin Exp Allergy 30:461-468, 2000. (Pubitemid 30253183)
46. Gonzalez JP, and Brogden RN. Nedocromil sodium. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of reversible obstructive airways disease. Drugs 34:560-577, 1987. (Pubitemid 17147673)
47. Kjellman NI, and Stevens MT. Clinical experience with Tilavist: An overview of efficacy and safety. Allergy 50:14-22, 1995.
48. Abelson MB, Berdy GJ, Mundorf T, et al. Pemirolast potassium 0.1% ophthalmic solution is an effective treatment for allergic conjunctivitis: A pooled analysis of two prospective, randomized, double-masked, placebo-controlled, phase III studies. J Ocul Pharmacol Ther 18:475-488, 2002. (Pubitemid 37420256)
49. Minami K, Hossen MA, and Kamei C. Increasing effect by simultaneous use of levocabastine and pemirolast on experimental allergic conjunctivitis in rats. Biol Pharm Bull 28:473-476, 2005. (Pubitemid 40879970)
50. Bielory L, and Ghafoor S. Histamine receptors and the conjunctiva. Curr Opin Allergy Clin Immunol 5:437-440, 2005. (Pubitemid 41345313)
51. Tomioka H, Yoshida S, Tanaka M, et al. Inhibition of chemical mediator release from human leukocytes by a new antiasthma drug, HC 20-511 (ketotifen). Monogr Allergy 14:313-317, 1979.
52. Avunduk AM, Tekelioglu Y, Turk A, et al. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivitis: A 30-day, randomized, double-masked, artificial tear substitute-controlled trial. Clin Ther 27:1392-1402, 2005. (Pubitemid 41598370)
53. Aguilar AJ. Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate. Acta Ophthalmol Scand Suppl 230:52-55, 2000.
54. Sharif NA, Xu SX, Miller ST, et al. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases. J Pharmacol Exp Ther 278:1252-1261, 1996. (Pubitemid 27166976)
55. Sharif NA, Xu SX, and Yanni JM. Olopatadine (AL-4943A): Ligand binding and functional studies on a novel, long acting H1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis. J Ocul Pharmacol Ther 12:401-407, 1996. (Pubitemid 26405744)
56. Yanni JM, Weimer LK, Sharif NA, et al. Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs. Arch Ophthalmol 117:643-647, 1999.
57. Lippert U, Moller A, Welker P, et al. Inhibition of cytokine secretion from human leukemic mast cells and basophils by H1-and H2-receptor antagonists. Exp Dermatol 9:118-124, 2000. (Pubitemid 30192709)
58. Cook EB, Stahl JL, Barney NP, et al. Olopatadine inhibits TNFalpha release from human conjunctival mast cells. Ann Allergy Asthma Immunol 84:504-508, 2000. (Pubitemid 30365412)
59. Spangler DL, Bensch G, and Berdy GJ. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model. Clin Ther 23:1272-1280, 2001. (Pubitemid 32804119)
60. Kaliner MA, Oppenheimer J, and Farrar JR. Comprehensive review of olopatadine: The molecule and its clinical entities. Allergy Asthma Proc 31:112-119, 2010.
61. Bernstein JA. Azelastine hydrochloride: A review of pharmacology, pharmacokinetics, clinical efficacy and tolerability. Curr Med Res Opin 23:2441-2452, 2007. (Pubitemid 350033446)
62. Lieberman PL, and Settipane RA. Azelastine nasal spray: A review of pharmacology and clinical efficacy in allergic and nonallergic rhinitis. Allergy Asthma Proc 24:95-105, 2003. (Pubitemid 37034194)
63. Bielory L, Buddiga P, and Bigelson S. Ocular allergy treatment comparisons: Azelastine and olopatadine. Curr Allergy Asthma Rep 4:320-325, 2004. (Pubitemid 39359534)
64. Chand N, Pillar J, Diamantis W, et al. Inhibition of IgE-mediated allergic histamine release from rat peritoneal mast cells by azelastine and selected antiallergic drugs. Agents Actions 16: 318-322, 1985. (Pubitemid 15040971)
65. Shin MH, Baroody F, Proud D, et al. The effect of azelastine on the early allergic response. Clin Exp Allergy 22:289-295, 1992.
66. Brockman HL, Momsen MM, Knudtson JR, et al. Interactions of olopatadine and selected antihistamines with model and natural membranes. Ocul Immunol Inflamm 11:247-268, 2003. (Pubitemid 38021421)
67. Hanashiro K, Sunagawa M, Tokeshi Y, et al. Antiallergic drugs, azelastine hydrochloride and epinastine hydrochloride, inhibit ongoing IgE secretion of rat IgE-producing hybridoma FE-3 cells. Eur J Pharmacol 547:174-183, 2006. (Pubitemid 44373904)
68. Ciprandi G, Buscaglia S, Catrullo A, et al. Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert anti-allergic activity. Clin Exp Allergy 27:182-191, 1997. (Pubitemid 27085419)
69. Tasaka K. Epinastine: An update of its pharmacology, metabolism, clinical efficacy and tolerability in the treatment of allergic diseases. Drugs Today (Barc) 36:735-757, 2000. (Pubitemid 32016497)
70. Galatowicz G, Ajayi Y, Stern ME, et al. Ocular anti-allergic compounds selectively inhibit human mast cell cytokines in vitro and conjunctival cell infiltration in vivo. Clin Exp Allergy 37:1648-1656, 2007. (Pubitemid 47609843)
71. Hussar DA, and Abbas CA. New drugs: Asenapine, iloperidone, and bepotastine besilate. J Am Pharm Assoc (2003) 50:107-110, 2010.
72. Bepotastine (bepreve)-An ophthalmic H1-antihistamine. Med Lett Drugs Ther 52:11-12, 2010.
73. Abelson MB, Torkildsen GL, Williams JI, et al. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: A phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children. Clin Ther 31:1908-1921, 2009.
74. Greiner JV, Edwards-Swanson K, and Ingerman A. Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%. Clin Ophthalmol 5:87-93, 2011.
75. Bohets H, McGowan C, Mannens G, et al. Clinical pharmacology of alcaftadine, a novel antihistamine for the prevention of allergic conjunctivitis. J Ocul Pharmacol Ther 27:187-195, 2011.
76. Ousler GW III, Workman DA, and Torkildsen GL. An openlabel, investigator-masked, crossover study of the ocular drying effects of two antihistamines, topical epinastine and systemic loratadine, in adult volunteers with seasonal allergic conjunctivitis. Clin Ther 29:611-616, 2007. (Pubitemid 47016634)
77. Lekhanont K, Park CY, Combs JC, et al. Effect of topical olopatadine and epinastine in the botulinum toxin B-induced mouse model of dry eye. J Ocul Pharmacol Ther 23:83-88, 2007. (Pubitemid 46449306)
78. Villareal AL, Farley W, and Pflugfelder SC. Effect of topical ophthalmic epinastine and olopatadine on tear volume in mice. Eye Contact Lens 32:272-276, 2006. (Pubitemid 44747200)
79. Bielory L. Update on ocular allergy treatment. Expert Opin Pharmacother 3:541-553, 2002. (Pubitemid 34520864)
80. Bielory L. Ocular allergy guidelines: A practical treatment algorithm. Drugs 62:1611-1634, 2002. (Pubitemid 34848369)
81. Dell SJ, Lowry GM, Northcutt JA, et al. A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis. J Allergy Clin Immunol 102:251-255, 1998.
82. Dell SJ, Shulman DG, Lowry GM, et al. A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol Allergic Conjunctivitis Study Group. Am J Ophthalmol 123:791-797, 1997. (Pubitemid 27250926)
83. Bielory BP, Perez VL, and Bielory L. Treatment of seasonal allergic conjunctivitis with ophthalmic corticosteroids: In search of the perfect ocular corticosteroids in the treatment of allergic conjunctivitis. Curr Opin Allergy Clin Immunol 10: 469-477, 2010.
84. Hochhaus G, Chen LS, Ratka A, et al. Pharmacokinetic characterization and tissue distribution of the new glucocorticoid soft drug loteprednol etabonate in rats and dogs. J Pharm Sci 81:1210-1215, 1992. (Pubitemid 23018130)
85. Settipane G, Korenblat PE, Winder J, et al. Triamcinolone acetonide Aqueous nasal spray in patients with seasonal ragweed allergic rhinitis: A placebo-controlled, double-blind study. Clin Ther 17:252-263, 1995.
86. Welsh PW, Stricker WE, Chu CP, et al. Efficacy of beclomethasone nasal solution, flunisolide, and cromolyn in relieving symptoms of ragweed allergy. Mayo Clin Proc 62:125-134, 1987. (Pubitemid 17016454)
87. Tinkelman D, Falliers C, Gross G, et al. Multicenter evaluation of triamcinolone acetonide nasal aerosol in the treatment of adult patients with seasonal allergic rhinitis. Ann Allergy 64:234-240, 1990. (Pubitemid 20067107)
88. Condemi J, Schulz R, and Lim J. Triamcinolone acetonide aqueous nasal spray versus loratadine in seasonal allergic rhinitis: Efficacy and quality of life. Ann Allergy Asthma Immunol 84:533-538, 2000. (Pubitemid 30365417)
89. Giger R, Pasche P, Cheseaux C, et al. Comparison of onceversus twice-daily use of beclomethasone dipropionate aqueous nasal spray in the treatment of allergic and non-allergic chronic rhinosinusitis. Eur Arch Otorhinolaryngol 260:135-140, 2003. (Pubitemid 36437750)
90. Moller C, Ahlstrom H, Henricson KA, et al. Safety of nasal budesonide in the long-term treatment of children with perennial rhinitis. Clin Exp Allergy 33:816-822, 2003. (Pubitemid 36760515)
91. Bernstein DI, Levy AL, Hampel FC, et al. Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis. Clin Exp Allergy 34:952-957, 2004. (Pubitemid 38824075)
92. Kaiser HB, Naclerio RM, Given J, et al. Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 119:1430-1437, 2007. (Pubitemid 46855849)
93. Bielory L, and Friedlaender MH. Allergic conjunctivitis. Immunol Allergy Clin North Am 28:43-58, 2008. (Pubitemid 351241107)
94. Hong J, Bielory B, Rosenberg JL, et al. Efficacy of intranasal corticosteroids for the ocular symptoms of allergic rhinitis: A systematic review. Allergy Asthma Proc 32:22-35, 2011.
95. Bui CM, Chen H, Shyr Y, et al. Discontinuing nasal steroids might lower intraocular pressure in glaucoma. J Allergy Clin Immunol 116:1042-1047, 2005. (Pubitemid 41571785)
96. Lallemand F, Felt-Baeyens O, Besseghir K, et al. Cyclosporine A delivery to the eye: A pharmaceutical challenge. Eur J Pharm Biopharm 56:307-318, 2003. (Pubitemid 37346503)
97. Kilic A, and Gurler B. Topical 2% cyclosporine A in preservative-free artificial tears for the treatment of vernal keratoconjunctivitis. Can J Ophthalmol 41:693-698, 2006. (Pubitemid 46113021)
98. Yoshida A, Fujihara T, and Nakata K. Cyclosporin A increases tear fluid secretion via release of sensory neurotransmitters and muscarinic pathway in mice. Exp Eye Res 68:541-546, 1999. (Pubitemid 29244140)
99. Lowell F, and Franklin W. A double-blind study of the effectiveness and specificity injection therapy in ragweed hay fever. N Engl J Med 273:675-679, 1965.
100. Del Prete A, Loffredo C, Carderopoli A, et al. Local specific immunotherapy in allergic conjunctivitis. Acta Ophthalmol (Copenh) 72:631-634, 1994. (Pubitemid 24370776)
101. Juniper EF, Kline PA, Ramsdale EH, et al. Comparison of the efficacy and side effects of aqueous steroid nasal spray (budes-onide) and allergen-injection therapy (Pollinex-R) in the treatment of seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 85:606-611, 1990. (Pubitemid 20099004)
102. Gaglani B, Borish L, Bartelson BL, et al. Nasal immunotherapy in weed-induced allergic rhinitis. Ann Allergy Asthma Immunol 79:259-265, 1997. (Pubitemid 27499982)
103. Dreborg S, Agrell B, Foucard T, et al. A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporium herbarum preparation. I. Clinical results. Allergy 41:131-140, 1986. (Pubitemid 16044354)
104. Horak F, Stubner P, Berger UE, et al. Immunotherapy with sublingual birch pollen extract. A short-term double-blind placebo study. J Investig Allergol Clin Immunol 8:165-171, 1998. (Pubitemid 28342473)
105. Balda BR, Wolf H, Baumgarten C, et al. Tree-pollen allergy is efficiently treated by short-term immunotherapy (STI) with seven preseasonal injections of molecular standardized allergens. Allergy 53:740-748, 1998. (Pubitemid 28374754)
106. Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007.
107. Niggemann B, Jacobsen L, Dreborg S, et al. Five-year follow-up on the PAT study: specific immunotherapy and longterm prevention of asthma in children. Allergy 61:855-859, 2006. (Pubitemid 43893987)
108. Stelmach I, Kaczmarek-Wozniak J, Majak P, et al. Efficacy and safety of high-doses sublingual immunotherapy in ultra-rush scheme in children allergic to grass pollen. Clin Exp Allergy 39:401-408, 2009.
109. Pradalier A, Basset D, Claudel A, et al. Sublingual-swallow immunotherapy (SLIT) with a standardized five-grass-pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis. Allergy 54:819-828, 1999. (Pubitemid 29402164)
110. Durham SR and Riis B. Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage. Allergy 62:954-957, 2007. (Pubitemid 47037852)
111. Schacke H, Hennekes H, Schottelius A, et al. SEGRAs: A novel class of anti-inflammatory compounds. Ernst Schering Res Found Workshop 2002:357-371, 2002.
112. Shafiee A, Bucolo C, Budzynski E, et al. In vivo ocular efficacy profile of mapracorat, a novel selective glucocorticoid receptor agonist, in rabbit models of ocular disease. Invest Ophthalmol Vis Sci 52:1422-1430, 2011.
113. Schoepe S, Schacke H, Bernd A, et al. Identification of novel in vitro test systems for the determination of glucocorticoid receptor ligand-induced skin atrophy. Skin Pharmacol Physiol 23:139-151, 2010.